Virios Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Portfolio Pulse from Benzinga Newsdesk
Virios Therapeutics has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, as its shares closed at or above the threshold for 10 consecutive business days.

May 25, 2023 | 8:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Virios Therapeutics' stock (VIRI) has regained compliance with Nasdaq's minimum bid price requirement, potentially boosting investor confidence.
Regaining compliance with Nasdaq's minimum bid price requirement is a positive development for Virios Therapeutics. This news may boost investor confidence in the stock, as it indicates that the company has met a key listing requirement, reducing the risk of delisting. As a result, the stock price may experience a short-term positive impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100